Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome.
about
Is lipid signaling through cannabinoid 2 receptors part of a protective system?Toward more predictive genetic mouse models of Alzheimer's diseaseSite-specific and time-dependent activation of the endocannabinoid system after transection of long-range projectionsBrain CB₂ Receptors: Implications for Neuropsychiatric Disorders.The endocannabinoid system as a target for the treatment of neurodegenerative disease.Epigenetic regulation of fatty acid amide hydrolase in Alzheimer diseaseCannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target.Molecular reorganization of endocannabinoid signalling in Alzheimer's diseaseCannabinoid receptor expression in HIV encephalitis and HIV-associated neuropathologic comorbidities.An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease.The therapeutic potential of cannabinoids for movement disorders.Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotectionCannabinoid CB2 Receptors in a Mouse Model of Aβ Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of NeuroinflammationUpdate on the role of cannabinoid receptors after ischemic stroke.Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands.Role of cannabinoids and endocannabinoids in cerebral ischemia.Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias.The endocannabinoid system as a target for the treatment of neuronal damage.The multiplicity of action of cannabinoids: implications for treating neurodegeneration.Prospects for cannabinoid therapies in basal ganglia disorders.Cannabinoids, multiple sclerosis and neuroprotection.The therapeutic potential of the endocannabinoid system for Alzheimer's disease.The influence of cannabinoids on generic traits of neurodegeneration.A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.Pharmacological hypothermia: a potential for future stroke therapy?Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia.β-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-α, PPAR-γ and TRPV1, but not CB₁ or CB₂ receptors.Differential Effects of Palmitoylethanolamide against Amyloid-β Induced Toxicity in Cortical Neuronal and Astrocytic Primary Cultures from Wild-Type and 3xTg-AD Mice.Detailed characterisation of CB2 receptor protein expression in peripheral blood immune cells from healthy human volunteers using flow cytometry.
P2860
Q24633122-68B58BC1-F297-43FA-9169-33AB220AEF60Q26771883-548FFE35-DECD-42E4-A134-FEB1D0164E3BQ27306768-1419C02A-84FC-4A8A-A91B-EA53DE5FF46EQ33664105-0CB16094-846B-4DD3-B58A-C84350593CC2Q34098196-E2ABFF5E-08B9-4F0E-8807-FD580AD8560EQ34312272-959EE047-B249-4734-B9F7-9848A1C012A7Q34680801-E345612A-2822-4658-9161-E73149993F26Q34754667-8C2BE163-C9B5-4AC5-9B72-650544A81770Q35103574-836F624A-F0FF-4FA2-AF0E-17C00C172189Q35159081-3318D01D-FD20-4A06-8407-C2085B59B11DQ35171113-0A3D491B-AD3B-4038-8E85-01D5232381A9Q35499568-0C8C023A-64F9-4737-BCEA-C0E1AD4EE6A7Q35667387-360269E7-2095-4093-80A6-17D8E98DEADCQ35915645-871605DE-F33A-4552-BF80-3A2577071692Q36075529-90FF184B-B8C3-4142-A1C0-1204E7EDC029Q36967863-9E5CED85-6D49-4F05-BD37-AEC0CF503EBFQ37253331-254EEEC0-29C0-4C22-8B0A-96759FEFAF46Q37637769-6A039499-EF15-4512-8099-73B744117BB2Q37709370-46E97A2A-0AC2-4032-86C7-7B11E058F76FQ37793366-F838E966-FF0C-4C02-B452-CDE06967A756Q37872326-13473B57-0239-4DED-8A5E-9DB46C3738CEQ37960199-19E75A38-600F-44B5-8C28-2D6144C85FB1Q37997020-D98948D1-9843-4E2A-8576-61F17E64CECDQ38156518-FF30E227-9779-4F35-A326-41CB0A4A9578Q38392800-C289BA6B-F623-4F26-A0A5-FCAB7C65B38FQ38851190-8EA400AF-FDF6-4CCD-B6F8-A6476AFAC11FQ39248070-D0E636C8-E021-4AAA-9DA3-076FE4BC0BCDQ42272971-7C18C6CD-1B24-497E-A8F4-C18A3C74D1E0Q42474130-1B7DCF80-1CF5-4C1E-B3B6-26DD712332ECQ46407462-7CFD1DB8-1C78-46EB-B1D1-974010B9E0FB
P2860
Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Glial expression of cannabinoid CB
@nl
Glial expression of cannabinoi ...... ked events in Down's syndrome.
@en
type
label
Glial expression of cannabinoid CB
@nl
Glial expression of cannabinoi ...... ked events in Down's syndrome.
@en
prefLabel
Glial expression of cannabinoid CB
@nl
Glial expression of cannabinoi ...... ked events in Down's syndrome.
@en
P2093
P921
P1433
P1476
Glial expression of cannabinoi ...... ked events in Down's syndrome.
@en
P2093
P304
P356
10.1016/J.NEUROSCIENCE.2007.10.029
P407
P577
2007-11-04T00:00:00Z